| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | EPSILON HEALTHCARE LIMITED: Shareholder Update | 1 | ASX | ||
| 25.09. | EPSILON HEALTHCARE LIMITED: Update to Appendix 4C Managing Director Loan | - | ASX | ||
| 17.09. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Zoe Hutchings | 1 | ASX | ||
| 15.09. | EPSILON HEALTHCARE LIMITED: Epsilon Progresses Global Manufacturing Opportunity | 2 | ASX | ||
| 10.09. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Alan Beasley | 1 | ASX | ||
| EPSILON HEALTHCARE Aktie jetzt für 0€ handeln | |||||
| 31.08. | EPSILON HEALTHCARE LIMITED: Half Yearly Report and Accounts | 1 | ASX | ||
| 30.07. | EPSILON HEALTHCARE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 09.07. | EPSILON HEALTHCARE LIMITED: Change in substantial holding | 1 | ASX | ||
| 08.07. | EPSILON HEALTHCARE LIMITED: Becoming a substantial holder | - | ASX | ||
| 06.07. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Zoe Hutchings | 1 | ASX | ||
| 30.06. | EPSILON HEALTHCARE LIMITED: Company Debt Arrangements - update | - | ASX | ||
| 26.06. | EPSILON HEALTHCARE LIMITED: Closure of small holding share sale facility | - | ASX | ||
| 09.06. | EPSILON HEALTHCARE LIMITED: Notification regarding unquoted securities - EPN | - | ASX | ||
| 09.06. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Alan Beasley | - | ASX | ||
| 09.06. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Peter Giannopoulos | - | ASX | ||
| 29.05. | EPSILON HEALTHCARE LIMITED: Results of Meeting | - | ASX | ||
| 11.05. | EPSILON HEALTHCARE LIMITED: Change of Director's Interest Notice - Alan Beasley | - | ASX | ||
| 08.05. | EPSILON HEALTHCARE LIMITED: Small holding share sale facility | - | ASX | ||
| 30.04. | EPSILON HEALTHCARE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 29.04. | EPSILON HEALTHCARE LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| CRONOS GROUP | 2,896 | +1,05 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| DIGICANN VENTURES | 0,007 | -26,32 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| INCYTE | 102,25 | -0,20 % | Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva | - Einmal täglich oral verabreichter ALK2-Hemmer erhält Zulassung zur Reduzierung des Volumens der gesamten neuen heterotopischen Verknöcherung bei Patienten mit FOP im Alter von über 12 Jahren ... ► Artikel lesen |